GW Pharmaceuticals has patented a CBD preparation with over 90% CBD and a specific ratio of THC is more effective in treating diseases. The presence of minor impurities like THC enhances the efficacy of CBD treatment, providing a synergistic effect. GlobalData’s report on GW Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on GW Pharmaceuticals, was a key innovation area identified from patents. GW Pharmaceuticals's grant share as of February 2024 was 49%. Grant share is based on the ratio of number of grants to total number of patents.
Cbd preparation with at least 90% cbd and thc
See Also:
A recently granted patent (Publication Number: US11865102B2) discloses a cannabidiol (CBD) preparation with a high concentration of CBD, greater than or equal to 90% (w/w) based on the total amount of cannabinoids in the preparation. The remaining cannabinoids in the preparation include tetrahydrocannabinol (THC), with a specific ratio of trans-THC to cis-THC ranging from about 0.7:1.0 to about 5.0:1.0. Additionally, the CBD preparation contains not more than 1.5% (w/w) THC, with specific ranges of THC content specified in the claims.
Furthermore, the patent covers the use of this CBD preparation in pharmaceutical compositions for treating epilepsy, specifically targeting conditions such as Dravet syndrome, Lennox Gastaut syndrome, Doose syndrome, or tuberous sclerosis complex (TSC). The method involves administering a therapeutically effective amount of the CBD preparation, with dosages ranging from about 5 mg/kg/day to about 50 mg/kg/day. Specific dosages for different types of epilepsy within the specified conditions are also outlined in the claims, providing a detailed guide for medical practitioners looking to utilize this CBD preparation for epilepsy treatment. The patent also includes provisions for the preparation of cannabinoids from cannabis plant material or synthetically, offering flexibility in the sourcing of the active ingredients for the CBD preparation.
To know more about GlobalData’s detailed insights on GW Pharmaceuticals, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
